Subscribe to MDT Magazine News

Jackson Lab cancer research gains $429K grant

April 13, 2011 10:40 am | by Mass High Tech: The Journal of New England Technology | Comments

A researcher at Jackson Laboratory in Bar Harbor, Maine, has received a $429,933 to expand her work in studying microRNA therapies for lung cancer.

ThermoGenesis Announces Registration of Res-Q in India; Commercial Sales Expected to Begin in Current Quarter

April 13, 2011 9:38 am | by Bio-Medicine.Org | Comments

RANCHO CORDOVA, Calif., April 13, 2011 /- ThermoGenesis Corp. (NASDAQ: KOOL ), a leading supplier of innovative products and services that process and store adult stem cells, said today that its Res-Q™60 BMC System (Res-Q) has been registered by the Central Drugs Standard Control...


Delcath Receives Notice of European Regulatory Approval for Hepatic CHEMOSATâ„¢ Delivery System

April 13, 2011 9:38 am | by Bio-Medicine.Org | Comments

NEW YORK, April 13, 2011 /- Delcath Systems, Inc. (NASDAQ: DCTH ) today announced that the Company has been notified of CE Mark approval for its proprietary Hepatic CHEMOSAT™ Delivery System. The product has been approved with an indication for the percutaneous intra-arterial...


Talyst Signs Vendor Agreement With H. D. Smith to Provide Quality- and Patient Safety-Enhancing Pharmacy Automation Solutions

April 13, 2011 8:37 am | by Bio-Medicine.Org | Comments

BELLEVUE, Wash., April 13, 2011 /- Talyst, Inc. , a leader in pharmacy automation, announced a vendor agreement with H. D. Smith, the fourth largest national pharmaceutical wholesaler, to provide the Company with leading pharmacy automation technology for its acute and extended care...


DOD grant prompts Marinus' Fragile X drug trial

April 13, 2011 8:35 am | by Mass High Tech: The Journal of New England Technology | Comments

The lead drug candidate of Marinus Pharmaceuticals Inc., a Branford, Conn.-based company focused on therapeutic developments for central nervous system disorders, is the target of a $3 million grant awarded by the U.S. Department of Defense to study treatment for Fragile-X syndrome.


CareFusion Will Host an Earnings Conference Call on May 5 to Discuss the Results for the Third Quarter Fiscal 2011

April 13, 2011 8:33 am | by Bio-Medicine.Org | Comments

SAN DIEGO, April 13, 2011 /- CareFusion Corporation (NYSE: CFN ), a global leading medical technology company, today announced plans to release third quarter fiscal 2011 results on Thursday, May 5 following the close of trading on the New York Stock Exchange. The company will host a...


FEI Canada Announces 2011 Frank S. Capon Distinguished Service Award Winners

April 13, 2011 6:45 am | by The Associated Press | Comments

Financial Executives International Canada (FEI Canada), the professional membership association for senior financial executives, is pleased to announce that Pierre Matuszewski, MBA, and Victor Wells, FCA, ICD.D, are the recipients of the 2011 Frank S. Capon Distinguished Service...

NeoStem's Subsidiary Progenitor Cell Therapy Receives FACT Accreditation for Its New Allendale, New Jersey Manufacturing Facility

April 13, 2011 6:36 am | by Bio-Medicine.Org | Comments

ALLENDALE, N.J., April 13, 2011 /- Progenitor Cell Therapy (PCT), a wholly owned subsidiary of NeoStem, Inc. (NYSE Amex: NBS ) and an internationally recognized cell therapy services and development company, announced today that it has, once again, demonstrated compliance with the...


Medical Device Industry Veteran Angela Horacek Joins AlloSource as VP of Operations

April 13, 2011 6:35 am | by Bio-Medicine.Org | Comments

CENTENNIAL, Colo., April 13, 2011 /- AlloSource, one of the nation's largest non-profit providers of skin, bone and soft tissue allografts for use in surgical procedures and the world's largest processor of live cellular bone growth substitutes, today announced the hire of Angela Horacek...


Experts at Experimental Biology examine dietary cholesterol, egg intake and heart disease risk

April 13, 2011 5:40 am | by EurekAlert | Comments

(Edelman Public Relations) This week at Experimental Biology (EB) 2011 in Washington, D.C., long-standing beliefs about dietary cholesterol intake and cardiovascular disease risk were examined as part of a scientific symposium and a variety of poster presentations. Experts from...


New Clinical Studies Reinforce the LAP-BAND® System is a Safe and Effective Weight-Loss Treatment for Obese Adults with Obesity-Related Comorbid Conditions

April 13, 2011 5:36 am | by Bio-Medicine.Org | Comments

IRVINE, Calif., April 13, 2011 /- Two new studies published in the current issue of Surgery for Obesity and Related Diseases, a peer-reviewed journal, add to the large body of scientific evidence which supports that the LAP-BAND® Adjustable Gastric Banding System, made by Allergan,...


ConvaTec Supported Studies to be Presented at the 24th Annual Symposium on Advanced Wound Care (SAWC) and Wound Healing Society (WHS)

April 13, 2011 5:36 am | by Bio-Medicine.Org | Comments

DALLAS, April 13, 2011 /- ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, today announced that data related to wound management will be presented at the 24th Annual Symposium on Advanced Wound Care and Wound Healing...


Taris Biomedical rounds up $18.3M in Series B financing

April 13, 2011 5:35 am | by Mass High Tech: The Journal of New England Technology | Comments

Taris Biomedical, a Lexington life sciences company developing combination drug-device products and co-founded by Michael Cima and Robert Langer, has taken in $18.3 million in a Series B funding round led by new investor Third Rock Ventures.


GE Healthcare Presents Interim Data on the Impact of DaTscanâ„¢ (Ioflupane I 123 Injection) SPECT Imaging on the Diagnosis and Clinical Management of Patients with Clinically Un...

April 13, 2011 5:33 am | by Bio-Medicine.Org | Comments

HONOLULU, April 13, 2011 /- Today, GE Healthcare announced interim results of a recently completed randomized study of the impact of DaTscan™ SPECT imaging on the clinical  management and diagnosis of adult patients who exhibit signs or symptoms of parkinsonian syndromes (PS)....


Medyssey Spine Receives 510(k) Clearance for Its LP Cage(TM) Posterior Lumbar Interbody Fusion System

April 13, 2011 3:37 am | by Bio-Medicine.Org | Comments

CHICAGO, April 13, 2011 /- Medyssey Co., Ltd., the parent company of Medyssey Spine , a spinal implant manufacturer focused on commercializing products for the surgical treatment of spine disorders, today announced that the Company has received 510(k) clearance from the FDA for its LP...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.